Aclaris Therapeutics
158 articles about Aclaris Therapeutics
-
Aclaris Therapeutics and Pediatrix Therapeutics Announce License Agreement for ATI-1777 in Greater China
11/29/2022
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, and Pediatrix Therapeutics, Inc. (Pediatrix), a pediatrics-focused therapeutic company, today announced that the companies have entered into a license agreement.
-
Aclaris Therapeutics Announces Key Leadership Transitions
11/22/2022
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, announced several key leadership changes.
-
Aclaris Therapeutics to Participate in Two November 2022 Healthcare Investor Conferences
11/10/2022
Aclaris Therapeutics, Inc. announced that the company will participate in two November healthcare investor conferences.
-
Aclaris Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
11/8/2022
Aclaris Therapeutics, Inc. today announced its financial results for the third quarter of 2022 and provided a corporate update.
-
Aclaris Therapeutics Appoints Robert Doody as Vice President, Investor Relations
9/27/2022
Aclaris Therapeutics, Inc. announced that it has appointed Robert A. Doody Jr. as Vice President, Investor Relations.
-
Aclaris Therapeutics Announces Patent License Agreement with Lilly for Alopecia Areata
8/25/2022
Aclaris Therapeutics, Inc. today announced a non-exclusive patent license agreement with Eli Lilly and Company (Lilly).
-
Aclaris Therapeutics to Participate in the Jefferies Healthcare Conference - June 01, 2022
6/1/2022
Aclaris Therapeutics, Inc. announced that Dr. Neal Walker, President and CEO of Aclaris, will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 11:30 a.m. ET in New York, New York.
-
Aclaris Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
5/16/2022
Aclaris Therapeutics, Inc. announced that Dr. Neal Walker, President and CEO of Aclaris, will virtually present a company overview at the H.C. Wainwright Global Investment Conference, which will be available beginning on Tuesday, May 24, 2022 at 7:00 a.m. ET.
-
Aclaris Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update
5/10/2022
Aclaris Therapeutics, Inc. announced its financial results for the first quarter of 2022 and provided a corporate update.
-
Aclaris Therapeutics to Participate in the LifeSci Partners Immunology & Inflammation Symposium
5/3/2022
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, President and CEO, and Walter Smith, Scientific and Business Development Consultant, of Aclaris will participate in a virtual fireside chat at the LifeSci Partners Immunology & Inflammation Symposium.
-
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update
2/24/2022
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the fourth quarter and full year of 2021 and provided a corporate update.
-
Aclaris Therapeutics to Participate in the SVB Leerink Virtual 11th Annual Global Healthcare Conference
2/2/2022
Aclaris Therapeutics, Inc. announced that Dr. Neal Walker, President and CEO of Aclaris, will participate in a fireside chat at the SVB Leerink Virtual 11th Annual Global Healthcare Conference on Wednesday, February 16, 2022 at 9:20 a.m. ET.
-
Aclaris Therapeutics Expands Leadership Team
2/1/2022
Aclaris Therapeutics, Inc. today announced the appointment of James Loerop as Chief Business Officer, effective January 31, 2022.
-
Aclaris Therapeutics Provides R&D Update
1/11/2022
Aclaris Therapeutics, Inc. provides an update on the status of certain of its clinical programs and on its research and development operations.
-
Aclaris Therapeutics to Participate in the H.C. Wainwright BioConnect Virtual Conference
12/27/2021
Aclaris Therapeutics, Inc. today announced that Dr. Neal Walker, President and CEO of Aclaris, will participate in a fireside chat at the H.C. Wainwright BioConnect Virtual Conference, which will be available beginning on Monday, January 10, 2022 at 7:00 a.m. ET.
-
Aclaris Therapeutics Announces Publication of Preclinical Research of Zunsemetinib in Pancreatic Cancer in Science Translational Medicine
12/3/2021
Aclaris Therapeutics, Inc. today announced the publication of preclinical research of zunsemetinib in pancreatic cancer in the peer-reviewed journal Science Translational Medicine, on December 1, 2021.
-
Aclaris Therapeutics to Host Virtual R&D Day on December 7, 2021
11/18/2021
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it will host a virtual R&D Day on Tuesday, December 7, 2021 from 10:00 a.m. to 12:00 p.m. ET.
-
Aclaris Therapeutics to Participate in Upcoming Investor Conferences - Nov 03, 2021
11/3/2021
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, announced that management will participate in the following upcoming investor conferences:
-
Aclaris Therapeutics Reports Third Quarter 2021 Financial Results and Provides a Corporate Update
11/2/2021
Aclaris Therapeutics, Inc. today announced its financial results for the third quarter of 2021 and provided a corporate update.
-
Aclaris Therapeutics to Participate in Upcoming Investor Conferences - Aug 26, 2021
8/26/2021
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, announced that management will participate in the following upcoming investor conferences: